Sangershi Risk Briefing Series: Antibiotic Drug Market Risk Analysis

Antibiotic Drug Market Risk Analysis Antibiotics are chemicals produced by microorganisms, including bacteria, fungi, line-out genus or higher plants and animals, that are resistant to pathogens or other activities in the course of life and that interfere with the developmental function of other living cells.
commonly used antibiotics are extracts from microbial cultures and chemically synthesized or semi-synthetic compounds. Antibacterial or sterilization effects of antimicrobial agents such as
antibiotics, mainly targeting bacteria and other mechanisms not found in human or other plants and animals, contain four mechanisms of action: inhibiting bacterial cell wall synthesis, enhancing bacterial cell membrane permeability, interfering with bacterial protein synthesis, and inhibiting bacterial nucleic acid replication transcription.
Antibiotics can be divided into: quinone antibiotics, β-endamide antibiotics, large ring esters, amino glycoside antibiotics, etc., according to their use can be divided into anti-bacterial antibiotics, antifactoxic antibiotics, anti-tumor antibiotics, antiviral antibiotics, animal antibiotics, agricultural antibiotics and other microbial drugs.
cephalosporins account for about 25 per cent of the global market share, followed by penicillin and about 20 per cent, and fluoroquinoquinols for about 15 per cent.
penicillin industrial salts, 6-APA, 7-ACA, 7-ADCA, 4-AA and erythromycin thiocyanate are the main raw materials and intermediates for these antibiotics.
Penicillin industrial salt is the raw material of all penicillin and some cephalosporin antibiotics, is a key link in the antibiotic industry, China is a large producer of penicillin industrial salt, mainly used as 6-APA raw materials and exports; Preparation of semi-synthetic penicillin raw materials for the synthesis of amoxicillin, 7-ACA is an intermediate of cephalosporin antibiotics for the synthesis of cephalosporine , cephalosporin and cephalosporine, etc.; 7-ADCA is a semi-synthetic antibiotic intermediate for cephalosporine, etc.; 4-AA is all carbon penicillin. A key common intermediate for southern antibiotic products for the synthesis of erythromycin and melobenan, etc., and erythromycin thiocyanate is the mother nuclei of the antibiotic apides of large ring esters, used for the synthesis of erythromycin, amber erythromycin and kramycin.
1. Antibiotic abuse antibiotic resistance affects the use of some major categories of antibiotics, with about 50% of the world's antibiotics abused each year, and the results of the national bacterial resistance monitoring by the Ministry of Health of China in 2006-2007 show that the use of antimicrobial drugs in hospitals nationwide is 74%.
then developed country hospital antibiotic use rate of 22%-25%.
and are readily available at home, to some extent leading to the misuse and misuse of antibiotics.
2. Overcapacity In 2018, China's production of antibiotic raw materials is about 196,000 tons, taking penicillin industrial salt as an example, the current domestic production capacity has reached 100,000 tons / year, and the total annual global market demand is only 56,000 tons.
but Huaxing Pharmaceuticals, Federal Pharmaceuticals, Wichida Pharmaceuticals, Health Yuan, Ha Pharmaceutical Group, Qilu Pharmaceuticals, the main production enterprises are increasing production capacity.
the same overcapacity problem with amosicillin and erythromycin thiocyanate, and several companies have pulled out of production.
3. Under the influence of the policy adjustment "restriction order" and environmental protection policy, the domestic antibiotic market has been greatly affected, and in recent years the State Health and Construction Commission and the Food and Drug Administration have issued policies to restrict the use of antibiotics, such as the Notice on the Continuous Management of The Clinical Application of Antibacterial Drugs, the Notice on Further Strengthening the Clinical Application Management of Antimicrobial Drugs to Curb Bacterial Resistance, and the Notice on the Issuance of the National Action Plan to Curb Bacterial Resistance (2016-2020).